Alexandre Merieux - BioMérieux CEO, Director and Member of Strategy Committee
| BMXMF Stock | USD 126.40 2.66 2.15% |
CEO
Mr. Alexandre Merieux has served as Chairman of the Board, Chairman of the Executive Committee, Chief Executive Officer, NonIndependent Director since December 15, 2017. He was prior Chief Operating Officer from January 1, 2017 to December 15, 2017. Mr. Alexandre Merieux was Chief Executive Officer, Member of the Management Committee and Director at Biomerieux SA. He previously worked for the Company as Deputy Chief Executive Officer, Corporationrationrate Vice President Industrial Microbiology, Member of the Management Committee and Director from December 19, 2008 to March 31, 2011. Prior to that, he was the Company Corporationrationrate Vice President Industrial Microbiology, Member of the Management Committee and Director until December 19, 2008. He was first appointed to the Company Board of Directors on April 16, 2004. From 1999 to 2004, Mr. Merieux served at the Silliker Group Corporationrationration, working in marketing in the United States and Europe and as Marketing and Business Unit director in France. He joined the Industrial Microbiology division of BioMerieux Inc in 2005. Mr. Merieux holds a degree in Biology from Universite Claude Bernard Lyon I and is a graduate of HEC Montreal Business School . He currently also holds several other posts, including Chairman of SGH, Director of Fondation Christophe et Rodolphe Merieux and Director of bioMerieux China Ltd., among others. since 2017.
| Age | 49 |
| Tenure | 8 years |
| Phone | 33 4 78 87 20 00 |
| Web | https://www.biomerieux.com |
BioMérieux Management Efficiency
The company has return on total asset (ROA) of 0.1008 % which means that it generated a profit of $0.1008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1751 %, meaning that it generated $0.1751 on every $100 dollars invested by stockholders. BioMérieux's management efficiency ratios could be used to measure how well BioMérieux manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Peter Maag | Caredx Inc | 58 | |
| Keith Sullivan | Neuronetics | 67 | |
| Udit Batra | Waters | 54 | |
| Oliver Filliol | Mettler Toledo International | 54 | |
| Timothy Damadian | Fonar | 60 | |
| Rainer Blair | Danaher | 61 | |
| John Hanna | Caredx Inc | 45 | |
| JoAnn Reed | Waters | 64 | |
| Marc Casper | Thermo Fisher Scientific | 57 | |
| Thomas Joyce | Danaher | 58 | |
| Michael McMullen | Agilent Technologies | 63 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
| Jacob Thaysen | Illumina | 50 | |
| Patrick Kaltenbach | Mettler Toledo International | 62 | |
| Helmy Eltoukhy | Guardant Health | 46 | |
Management Performance
bioMrieux SA Leadership Team
Elected by the shareholders, the BioMérieux's board of directors comprises two types of representatives: BioMérieux inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioMérieux. The board's role is to monitor BioMérieux's management team and ensure that shareholders' interests are well served. BioMérieux's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioMérieux's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Guillaume Bouhours, Corporate Vice President CFO, Member of the Executive Board | ||
| Frederic Beseme, Head CSR | ||
| Pierre Boulud, Corporate Vice-President Asia-Pacific Region, Industrial Unit, Investments and Strategic Planning | ||
| Franois Lacoste, Ex RD | ||
| Mark Miller, Member of the Management Committee, Chief Medical Officer and Head of Regulatory Affairs | ||
| Alexandre Merieux, CEO, Director and Member of Strategy Committee | ||
| Valerie Leylde, Communications HR | ||
| Yasha Mitrotti, Corporate Vice President Europe, Middle East, Africa Region, Member of the Management Committee | ||
| Pierre Charbonnier, Corporate Vice President Manufacturing & Supply Chain, Member of the Management Committee | ||
| Sylvain Morgeau, Head of Investor Relations |
BioMérieux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioMérieux a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.99 B | |||
| Shares Outstanding | 118.37 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 18.40 % | |||
| Price To Earning | 23.91 X | |||
| Price To Book | 3.18 X |
Currently Active Assets on Macroaxis
Other Information on Investing in BioMérieux Pink Sheet
BioMérieux financial ratios help investors to determine whether BioMérieux Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMérieux with respect to the benefits of owning BioMérieux security.